Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) has appointed Dallan Murray as Chief Commercial Officer, effective immediately. Murray brings over 25 years of experience in commercial strategy and global product launches from companies including Sarepta Therapeutics, where he achieved $1.8 billion in net product revenue in 2024.

Murray's extensive experience includes successful launches at major biotech companies, notably INCIVEK at Vertex Pharmaceuticals (fastest biotech launch to reach $1 billion), and strategic roles at Gilead Sciences, Biogen, and Johnson & Johnson. At Vor Bio, he will focus on commercialization strategy for telitacicept, which is currently approved in China for multiple autoimmune indications and advancing through global Phase 3 development.

Positive

• Appointment of highly experienced CCO with track record of successful product launches
• New CCO achieved $1.8B in net product revenue at Sarepta in 2024
• Telitacicept already approved in China for multiple autoimmune indications
• Product advancing through global Phase 3 development

Negative

• None.

Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities

CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately.

“We’re thrilled to welcome Dallan to Vor Bio at this important inflection point,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. “His track record of building high-performing commercial organizations and executing successful product launches will be instrumental as we prepare for potential commercialization of telitacicept and shape our broader growth strategy.”

Mr. Murray brings more than 25 years of experience leading commercial strategy, global product launches, and customer-facing organizations in biotechnology and pharmaceutical companies. He joins Vor Bio from Sarepta Therapeutics, where he most recently served as Executive Vice President, Chief Customer Officer. In that role, he led the commercial and medical affairs organizations, along with the international business unit. Under his leadership, Sarepta achieved approximately $1.8 billion in net product revenue in 2024. While at Sarepta he oversaw multiple product launches, including the launch of the first RNA therapy and first gene therapy for duchenne muscular dystrophy. Over the course of his career, Mr. Murray has led or supported more than a dozen product launches, including INCIVEK at Vertex Pharmaceutics, Inc., the fastest launch to $1 billion in biotech history at the time, and multiple global rollouts at Gilead Sciences, Inc., Biogen Inc., and Johnson & Johnson. At Gilead, he oversaw the launch of VIREAD in hepatitis B and maintained leadership in the HBV market. While at Biogen, he played a key role in the reintroduction and global commercialization of TYSABRI for multiple sclerosis, helping drive adoption across North America and international markets. Mr. Murray holds an MBA from Queen’s University in Ontario, Canada, and a Bachelor of Commerce from the University of Alberta.

“Vor Bio is building a company with great potential,” said Mr. Murray. “With telitacicept already approved in China for multiple autoimmune indications and now advancing through global Phase 3 development, I look forward to the opportunity to bring a much-needed treatment to patients around the world. I’m excited to join the team and help lay the commercial and strategic foundation for long-term success.”

About Vor Bio

Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding Vor Bio’s development and commercialization plans for telitacicept, its ability to change the treatment landscape for patients with autoimmune conditions and other statements that are not historical fact. Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

Sarah Spencer
investors@vorbio.com

FAQ

Who is the new Chief Commercial Officer of Vor Bio (VOR)?

Dallan Murray has been appointed as Chief Commercial Officer of Vor Bio, effective immediately. He previously served as Executive Vice President, Chief Customer Officer at Sarepta Therapeutics.

What is Dallan Murray's experience in the biotech industry?

Murray has over 25 years of experience in commercial strategy and global product launches, including roles at Sarepta Therapeutics, Vertex Pharmaceuticals, Gilead Sciences, Biogen, and Johnson & Johnson. He achieved $1.8 billion in net product revenue at Sarepta in 2024.

What is the status of Vor Bio's telitacicept development?

Telitacicept is currently approved in China for multiple autoimmune indications and is advancing through global Phase 3 development.

What notable product launches has Dallan Murray overseen?

Murray led the launch of INCIVEK at Vertex (fastest biotech launch to reach $1 billion), VIREAD for hepatitis B at Gilead, and played a key role in TYSABRI's reintroduction for multiple sclerosis at Biogen.

What will be Dallan Murray's main focus at Vor Bio (VOR)?

Murray will focus on shaping the launch strategy and global market readiness for telitacicept and future pipeline opportunities at Vor Bio.